Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17255708 | NOVEL AGROCHEMICAL COMBINATIONS | December 2020 | June 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17116682 | PHARMACEUTICAL COMPOSITIONS AND METHODS | December 2020 | August 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17099366 | Methods of Preventing Occurrence of Cardiovascular Events | November 2020 | May 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17099167 | Methods of Preventing Cardiovascular Events in Residual Risk Dyslipidemic Populations | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17095327 | Methods of Preventing Cardiovascular Events in Residual Risk Dyslipidemic Populations | November 2020 | July 2022 | Abandon | 20 | 2 | 1 | Yes | Yes |
| 17053708 | MutL LOSS PREDICTS SENSITIVITY TO CDK4/6 INHIBITORS IN CANCER | November 2020 | August 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17082669 | TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM | October 2020 | March 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17083267 | Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof | October 2020 | January 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17078531 | COMPOUND ANTIOXIDANT PREPARATION FOR REDUCING THE NUMBER OF SOMATIC CELLS IN A LIVESTOCK ANIMAL AND A PREPARATION METHOD AND APPLICATION THEREOF | October 2020 | January 2024 | Allow | 39 | 1 | 1 | No | No |
| 17075864 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | October 2020 | February 2023 | Allow | 28 | 0 | 0 | No | No |
| 17028863 | STABLE PHARMACEUTICAL COMPOSITIONS OF DIHYDROERGOTAMINE MESYLATE | September 2020 | August 2023 | Allow | 34 | 1 | 1 | No | No |
| 17022180 | COMPOSITIONS COMPRISING 15-OHEPA AND METHODS OF USING THE SAME | September 2020 | August 2023 | Abandon | 35 | 0 | 1 | No | No |
| 17017881 | PHOTOSENSITISING COMPOSITION AND USES THEREOF | September 2020 | September 2022 | Abandon | 24 | 1 | 1 | No | No |
| 17017295 | COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION | September 2020 | May 2021 | Allow | 8 | 1 | 1 | No | No |
| 16945839 | CANNABINOID CO-DRUG COMPOUNDS | August 2020 | August 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 16965960 | Methods for Treating Sleep Apnea with Combinations of Atomoxetine and (R)-Oxybutynin | July 2020 | December 2023 | Allow | 40 | 1 | 1 | No | No |
| 16959929 | Treating Autoimmune Disorders with Chloroquine and/or Hydroxychloroquine | July 2020 | November 2023 | Abandon | 40 | 1 | 1 | No | No |
| 16919111 | BIODEGRADABLE POLYMERIC FILM INCLUDING EXTRACELLULAR MATRIX AND USE THEREOF | July 2020 | January 2024 | Abandon | 42 | 2 | 1 | No | No |
| 16959046 | FORMULATIONS, SYSTEMS, AND METHODS FOR THERAPEUTIC TREATMENT | June 2020 | April 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16907963 | 1,2,4-Trioxane compounds and compositions comprising the same for use in the treatment of COVID-19 | June 2020 | December 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16901241 | pH RESPONSIVE MATERIALS FOR OPTICAL MONITORING OF WOUND STATUS | June 2020 | May 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16896311 | OPHTHALMIC PRODUCT WITH ANTIOXIDATIVE FUNCTION | June 2020 | June 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16895201 | LIPID NANOPARTICLES CONTAINING PHARMACEUTICAL AND/OR NUTRACEUTICAL AGENTS AND METHODS THEREOF | June 2020 | December 2023 | Abandon | 42 | 2 | 1 | No | No |
| 16892513 | METHODS OF TREATING HAIR RELATED CONDITIONS | June 2020 | July 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16879207 | STABLE LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING BENDAMUSTINE | May 2020 | April 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16763844 | Oral pharmaceutical composition containing pemetrexed and production method thereof | May 2020 | March 2023 | Allow | 34 | 2 | 1 | No | No |
| 16762361 | IONIC LIQUIDS FOR INTERNAL DELIVERY | May 2020 | June 2022 | Allow | 25 | 1 | 1 | No | No |
| 16863104 | COMBINATION OF TOPICAL MEDICATIONS FOR THE TREATMENT OF SKIN DISEASES AND METHODS OF USE | April 2020 | May 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 16759851 | ANTIMICROBIAL TETRAPEPTIDES | April 2020 | September 2022 | Abandon | 29 | 2 | 1 | Yes | No |
| 16851190 | PHARMACEUTICAL COMPOUNDS | April 2020 | February 2022 | Abandon | 22 | 1 | 1 | No | No |
| 16847988 | PRODRUGS OF FENCAMFAMINE | April 2020 | April 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 16754649 | LOW-TEMPERATURE STABLE OPIOID ANTAGONIST SOLUTIONS | April 2020 | February 2023 | Abandon | 34 | 1 | 1 | No | No |
| 16841776 | Method, Apparatus and Composition for Preventing Infection From Coronavirus, Limiting its Spread and Treatment Thereof | April 2020 | December 2021 | Abandon | 20 | 2 | 1 | Yes | No |
| 16838471 | NANOEMULSION CONCENTRATE FORMULATIONS AND METHODS | April 2020 | February 2024 | Abandon | 47 | 4 | 1 | No | No |
| 16837757 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | April 2020 | July 2021 | Allow | 16 | 0 | 1 | No | No |
| 16825441 | Method of treating and/ or preventing viral infection. | March 2020 | July 2022 | Abandon | 28 | 2 | 1 | Yes | No |
| 16821348 | CANCER TREATMENT WITH COMBINATION OF PLINABULIN AND TAXANE | March 2020 | January 2024 | Abandon | 46 | 3 | 1 | Yes | No |
| 16815967 | TREATMENTS OF OCULAR ALLERGY WITH ALCAFTADINE | March 2020 | July 2022 | Abandon | 29 | 1 | 1 | No | No |
| 16815569 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED BIOAVAILABILITY OF LIPOPHILIC ACTIVE PHARMACEUTICAL INGREDIENTS | March 2020 | January 2024 | Abandon | 47 | 3 | 1 | No | No |
| 16646120 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | March 2020 | June 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16813314 | TABLETS CONTAINING CILOFEXOR AND PHARMACEUTICALLY ACCEPTABLE CARRIERS | March 2020 | January 2023 | Abandon | 34 | 2 | 1 | No | No |
| 16644776 | ANALGESIC FORMULATION FOR CONTROL OF PAIN IN DOGS | March 2020 | June 2023 | Allow | 40 | 3 | 1 | Yes | No |
| 16644279 | COMPOSITION FOR CALCIUM SUPPLEMENTATION | March 2020 | November 2022 | Abandon | 32 | 2 | 1 | Yes | Yes |
| 16806120 | STABLE, LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING INSOLUBLE AND UNSTABLE DRUGS | March 2020 | March 2022 | Abandon | 24 | 1 | 1 | No | No |
| 16639669 | Application of Bi-Phenols in Anti-ototoxicity and Hearing Protection | February 2020 | August 2024 | Abandon | 54 | 4 | 1 | No | No |
| 16639423 | METHODS FOR TREATING ALZHEIMER'S DIEASE WITH RIFAPENTINE | February 2020 | January 2024 | Abandon | 47 | 7 | 1 | Yes | Yes |
| 16785917 | METHOD FOR TREATING SCHNITZLER�S SYNDROME | February 2020 | January 2023 | Abandon | 35 | 2 | 1 | No | No |
| 16782842 | COMPOSITION FOR PREVENTING AND TREATING PANCREATITIS CONTAINING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT | February 2020 | January 2023 | Abandon | 35 | 3 | 1 | No | No |
| 16636608 | METHODS OF TREATMENT | February 2020 | June 2023 | Abandon | 41 | 3 | 1 | No | No |
| 16633048 | LIQUID DOSAGE FORMS OF IMATINIB | January 2020 | February 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16732914 | PLANT PHENOLS AND THEIR USE IN THE TREATMENT OR PREVENTION OF EOSINOPHILIC ESOPHAGITIS | January 2020 | March 2022 | Allow | 26 | 1 | 1 | Yes | No |
| 16730591 | COMPOSITIONS AND METHODS OF USE OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE | December 2019 | November 2023 | Abandon | 47 | 3 | 1 | No | No |
| 16722699 | FORMULATIONS OF BRINCIDOFOVIR | December 2019 | July 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16625271 | ABUSE DETERRENT ORAL SOLID DOSAGE FORM | December 2019 | April 2022 | Allow | 28 | 2 | 0 | No | No |
| 16624814 | Compositions and methods for reducing methane producing bacteria in animals | December 2019 | February 2024 | Allow | 50 | 5 | 1 | No | No |
| 16718342 | PROCESSES FOR THE PREPARATION OF AMORPHOUS TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND A PREMIX THEREOF | December 2019 | December 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16705925 | METHOD FOR MEASURING AND MANAGING RED BLOOD CELL OMEGA-3 FATTY ACID DOCOSAHEXAENOIC ACID LEVEL IN HUMAN FEMALES TO SUPPORT A TERM PREGNANCY AND REDUCE RISK OF SPONTANEOUS PRETERM BIRTH | December 2019 | August 2024 | Abandon | 56 | 2 | 1 | No | No |
| 16704447 | PHARMACEUTICALS COMPOSITIONS FOR TREATMENT OF ATOPIC DERMATITIS | December 2019 | November 2021 | Abandon | 24 | 0 | 1 | No | No |
| 16704800 | 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF | December 2019 | July 2022 | Abandon | 31 | 1 | 1 | No | No |
| 16694408 | PHARMACEUTICAL FORMULA FOR THE TREATMENT AND/OR PREVENTION OF ARTHRITIS AND ITS MANUFACTURE | November 2019 | December 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16687151 | Thromboxane Receptor Antagonists in AERD/Asthma | November 2019 | October 2022 | Allow | 35 | 3 | 1 | Yes | No |
| 16684869 | USE OF AGENTS THAT ALTER THE PERITUMORAL ENVIRONMENT FOR THE TREATMENT OF CANCER | November 2019 | December 2021 | Abandon | 25 | 1 | 1 | No | No |
| 16682476 | USE OF TAPINAROF FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS | November 2019 | May 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16681361 | Cannabidiol Sublingual Spray Formulations | November 2019 | December 2021 | Abandon | 25 | 0 | 1 | No | No |
| 16610431 | Iodinated Contract Medium for Use as a Medicament for Thyroid Radioprotection | November 2019 | August 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16672323 | DRUG COMPOSITIONS | November 2019 | September 2022 | Abandon | 34 | 2 | 1 | No | No |
| 16659343 | COMPOSITIONS AND METHODS FOR NANOPARTICLE-BASED DRUG DELIVERY AND IMAGING | October 2019 | April 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16607032 | TRAMETINIB PREVENTS MESOTHELIAL-MESENCHYMAL TRANSITION AND AMELIORATES ABDOMINAL ADHESION AND PULMONARY FIBROSIS FORMATION | October 2019 | January 2024 | Allow | 51 | 4 | 1 | Yes | No |
| 16653591 | Phospholipid Compositions | October 2019 | April 2022 | Allow | 30 | 1 | 1 | No | No |
| 16601270 | GRANULATED COMPOSITE, RAPID RELEASE TABLET AND METHOD FOR PRODUCING SAME | October 2019 | March 2023 | Allow | 41 | 3 | 1 | No | No |
| 16497305 | APPLICATIONS OF SPERMINE AND ITS DERIVATIVE IN PREPARATION OF ANTITUMOR DRUG | September 2019 | January 2023 | Allow | 40 | 2 | 1 | Yes | No |
| 16497441 | METHOD FOR MEASURING WET FRICTION OF HAIR | September 2019 | September 2023 | Allow | 48 | 1 | 1 | Yes | No |
| 16579591 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | September 2019 | March 2021 | Abandon | 18 | 2 | 0 | No | Yes |
| 16579581 | AMORPHOUS SOLID FORM OF COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND SODIUM CATIONS | September 2019 | July 2021 | Allow | 21 | 3 | 0 | Yes | Yes |
| 16569927 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | September 2019 | January 2021 | Allow | 16 | 0 | 1 | No | No |
| 16492908 | BACTERIAL EFFLUX PUMP INHIBITORS | September 2019 | November 2023 | Allow | 50 | 3 | 1 | Yes | No |
| 16562515 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASE AND/OR SYMPTOMS IN ARTHRITIS | September 2019 | November 2021 | Abandon | 26 | 1 | 1 | No | No |
| 16538525 | HYALURONIC ACID COMPOSITIONS INCLUDING MEPIVACAINE | August 2019 | April 2021 | Abandon | 20 | 0 | 1 | No | No |
| 16533226 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | August 2019 | August 2020 | Allow | 13 | 0 | 0 | Yes | No |
| 16480691 | METHODS FOR PHOTOBIOMODULATION OF BIOLOGICAL PROCESSES USING FLUORESCENCE GENERATED AND EMITTED FROM A BIOPHOTONIC COMPOSITION OR A BIOPHOTONIC SYSTEM | July 2019 | October 2023 | Abandon | 51 | 1 | 1 | No | No |
| 16521035 | COMPOSITIONS FOR THE TREATMENT OF CATARACTS | July 2019 | March 2021 | Abandon | 20 | 0 | 1 | No | No |
| 16515653 | Stabilized Aqueous Compositions of Neuromuscular Blocking Agents | July 2019 | March 2024 | Allow | 56 | 6 | 1 | Yes | No |
| 16508630 | METHODS OF TREATING LEUKEMIA USING COMPOSITIONS CONTAINING BIS(BENZYLTHIO)OCTANOIC ACID AND ION PAIRS THEREOF | July 2019 | March 2021 | Allow | 20 | 1 | 0 | No | No |
| 16502811 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | July 2019 | June 2021 | Abandon | 23 | 2 | 0 | No | Yes |
| 16502821 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS | July 2019 | December 2021 | Abandon | 30 | 3 | 0 | No | Yes |
| 16445441 | SURFACTANT COMPOSITION BASED ON GLYCINE BETAINE AMIDE SALTS, PROCESS FOR PREPARING SAME AND USES THEREOF | June 2019 | September 2021 | Allow | 26 | 1 | 1 | No | No |
| 16427182 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS | May 2019 | December 2022 | Allow | 42 | 3 | 1 | No | No |
| 16405643 | ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS | May 2019 | September 2021 | Allow | 29 | 1 | 1 | No | No |
| 16345114 | STABLE PHARMACEUTICAL COMPOSITION | April 2019 | January 2021 | Abandon | 21 | 0 | 1 | No | No |
| 16344714 | METHOD FOR PRODUCING SUSPENDED FORM OF GROUND DECELLULARIZED EXTRACELLULAR MATRIX | April 2019 | January 2021 | Allow | 21 | 0 | 1 | No | No |
| 16343914 | EXTENDED RELEASE TABLET COMPRISING A WEIGHT-LOSS DRUG | April 2019 | May 2023 | Allow | 49 | 6 | 1 | Yes | No |
| 16384589 | COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES | April 2019 | July 2022 | Abandon | 39 | 3 | 1 | Yes | No |
| 16342172 | METHOD OF PROTECTING KERATIN MATERIALS FROM POLLUTANTS | April 2019 | September 2023 | Abandon | 53 | 6 | 1 | No | No |
| 16377428 | SULFONAMIDE PHARMACEUTICAL COMPOSITION | April 2019 | May 2021 | Allow | 25 | 1 | 1 | No | No |
| 16335732 | LIPOIC ACID CHOLINE ESTER COMPOSITIONS AND METHODS TO STABILIZE INTO PHARMACEUTICALLY RELEVANT DRUG PRODUCTS | March 2019 | February 2024 | Abandon | 59 | 0 | 1 | No | No |
| 16295577 | TREATMENT OF UTERINE FIBROIDS BY INTRAVAGINAL ADMINISTRATION OF A LOW DOSE OF SELECTIVE PROGESTERONE RECEPTOR MODULATOR (SPRM), ANTI-PROGESTIN, OR ANTI-PROGESTATIONAL AGENT | March 2019 | August 2023 | Abandon | 53 | 5 | 1 | No | No |
| 16326525 | ESTROGEN RECEPTOR BETA SELECTIVE LIGANDS | February 2019 | June 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16259441 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | January 2019 | August 2022 | Allow | 42 | 2 | 1 | Yes | No |
| 16254333 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | January 2019 | March 2022 | Abandon | 38 | 3 | 1 | Yes | No |
| 16240761 | PHARMACEUTICAL FORMULATIONS CONTAINING IPIDACRINE AND THEIR USE FOR THE TREATMENT OF DISORDERS OF POTENCY AND DISORDERS OF OTHER FORMS OF SEXUAL ACTIVITY | January 2019 | November 2020 | Abandon | 23 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner THOMAS, TIMOTHY P.
With a 42.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner THOMAS, TIMOTHY P works in Art Unit 1611 and has examined 253 patent applications in our dataset. With an allowance rate of 34.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner THOMAS, TIMOTHY P's allowance rate of 34.0% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by THOMAS, TIMOTHY P receive 3.00 office actions before reaching final disposition. This places the examiner in the 84% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by THOMAS, TIMOTHY P is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +29.1% benefit to allowance rate for applications examined by THOMAS, TIMOTHY P. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 8.1% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 13.5% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 34.5% of appeals filed. This is in the 6% percentile among all examiners. Of these withdrawals, 30.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 80.6% are granted (fully or in part). This grant rate is in the 84% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.3% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.